The first drug for MCT8 deficiency does not fix the gene

The transporter is called MCT8. When it is broken, thyroid hormone cannot enter the cells that need it, and the level in the blood climbs. The condition is Allan-Herndon-Dudley syndrome. Children with it have a profound intellectual disability and a metabolism that will not settle.

On 28 September 2026 the FDA approved Emcitate, tiratricol, the first treatment. Tiratricol gets into cells without the transporter. Blood hormone falls. The Federal Register published the rare-pediatric-disease priority review voucher on 28 October.

Key Facts

• FDA approval 28 September 2026. Voucher notice 28 October 2026, 91 FR 67840.
• Emcitate (tiratricol), Rare Thyroid Therapeutics International AB.
• First FDA-approved therapy for peripheral thyrotoxicosis in MCT8 deficiency.
• Enters cells without MCT8. Must not be combined with another thyroid medicine.
• Evidence includes a randomised trial, NCT05579327, plus a longer open-label study.

Why This Matters

Families had no approved drug. A molecule that bypasses the broken transporter is a real, narrow, prescribed thing, not a mouse result. The FDA granted it orphan, fast track, breakthrough, and priority review.

What We Don't Know Yet

It treats the high hormone in the blood. It does not repair the gene, and it does not undo developmental injury already done. The patient population is very small. Long-term safety is still being collected.

Sources: Federal Register · FDA